{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:32:26Z","timestamp":1786739546807,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>This is a case report of a uterine cancer with the International Federation of Gynecology and Obstetrics staging 3c2 with the initial clinical presentation of postmenopausal vaginal bleeding in August 2015. Endometrium biopsy showed invasive nests of poorly differentiated grade 3 endometrioid adenocarcinoma. The patient received robotic surgery including total hysterectomy, bilateral salpingo-oophorectomy, bilateral pelvic lymph node dissection, para-aortic lymph node dissection, and washing cytology. The final pathology showed an endometrioid carcinoma with myometrium invasion up to 85% and para-aortic and pelvic lymph nodes invasion. The patient received six courses of adjuvant chemotherapy (paclitaxel and carboplatin) with concurrent chemoradiotherapy after the surgery. Later, immunotherapy with Picibanil (OK-432) and interleukin-2 (IL-2) was given, and cancer did not recur for 34 months until tumor recurrence at the liver dome and bilateral lung was noted by positron-emission tomography scan in July 2018. The patient received laparoscopic surgery for intra-abdominal tumor excision in December 2018, and the tumor found extended to the right diaphragm, liver surface, omentum, bilateral flank to pelvic peritoneum, Douglas pouch, and upper rectum. We continued the immunotherapy with OK-432, IL-2, Aldara cream (imiquimod), and later on, virotherapy (human papillomavirus vaccine). The immune risk profiles showed T\u2013cells' proliferation and alteration of the Th1\/Th2 activation after immunotherapy and virotherapy. Proctectomy with colon-anal anastomosis and cytoreduction surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) (doxorubicin and paclitaxel) was performed in January 2019. After the surgery, the patient received chemotherapy (topotecan, paclitaxel, lipodox, and carboplatin) and continued the immunotherapy. The immune risk profiles showed CD4, CD4\/CD8 increase after HIPEC and immunotherapy. The patient continued the therapy until May 2020.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/gmit.gmit_153_20","type":"journal-article","created":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:46:44Z","timestamp":1627951604000},"page":"191-194","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Immunomodulating Therapy by Picibanil-based Imiquimod and Virotherapy for Advanced Uterine Cancer after Laparoscopic Surgery"],"prefix":"10.4103","volume":"10","author":[{"given":"Hsiu-Huei","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo-Xin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chyi-Long","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Tao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20240830","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1634\/theoncologist.2016-0062","article-title":"Chemotherapy for endometrial cancer in adjuvant and advanced disease settings","volume":"21","author":"Bestvina","year":"2016","journal-title":"Oncologist"},{"key":"R3-14-20240830","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/GRF.0000000000000513","article-title":"Immunotherapy for gynecologic cancer: Current applications and future directions","volume":"63","author":"Lynam","year":"2020","journal-title":"Clin Obstet Gynecol"},{"key":"R4-14-20240830","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2172-10-6","article-title":"Chemokines are secreted by monocytes following OK-432 (lyophilized Streptococcus pyogenes) stimulation","volume":"10","author":"Olsnes","year":"2009","journal-title":"BMC Immunol"},{"key":"R5-14-20240830","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4103\/GMIT.GMIT_1_19","article-title":"Immunotherapy with subcutaneous injection of immunomodulatory agent (OK-432) elicits durable response in locally advanced or relapsed cervical cancer","volume":"8","author":"Alas","year":"2019","journal-title":"Gynecol Minim Invasive Ther"},{"key":"R6-14-20240830","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4172\/2161-0932.1000415","article-title":"Efficacy of imiquimod cream administered intraperitoneally for ovarian metastases in colorectal cancer","volume":"6","author":"Lin","year":"2016","journal-title":"Gynecol Obstet (Sunnyvale"},{"key":"R7-14-20240830","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1073\/pnas.96.1.185","article-title":"A two-step, two-signal model for the primary activation of precursor helper T cells","volume":"96","author":"Bretscher","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R8-14-20240830","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/bs.pmbts.2015.09.001","article-title":"The molecular control of regulatory T cell induction","volume":"136","author":"van Nieuwenhuijze","year":"2015","journal-title":"Prog Md Biol Transt Sci"},{"key":"R9-14-20240830","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejmhg.2015.08.006","article-title":"Natural killer cells enhance the immune surveillance of cancer","volume":"17","author":"Nouroz","year":"2016","journal-title":"Egypt J Med Hum"},{"key":"R10-14-20240830","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1158\/0008-5472.CAN-18-0734","article-title":"Activation of NKT cells in an anti-PD-1 \u2013 Resistant tumor model enhances antitumor immunity by reinvigorating exhausted CD8 T cells","volume":"78","author":"Bae","year":"2018","journal-title":"Cancer Res"},{"key":"R11-14-20240830","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: Mechanistic basis and therapeutic strategies","volume":"35","author":"Vinay","year":"2015","journal-title":"Semin Cancer Biol"}],"container-title":["Gynecology and Minimally Invasive Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/GMIT.GMIT_153_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:29:55Z","timestamp":1786735795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/GMIT.GMIT_153_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/gmit.gmit_153_20","relation":{},"ISSN":["2213-3070"],"issn-type":[{"value":"2213-3070","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}